Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells.
Ileal lesions in 36.4% of patients with Crohn's disease are colonized by pathogenic adherent-invasive Escherichia coli. The aim of this study was to determine the in vitro inhibitory effects of the probiotic strain, Lactobacillus casei DN-114 001, on adhesion to and invasion of human intestinal epithelial cells by adherent-invasive E. coli isolated from Crohn's disease patients. The experiments were performed with undifferentiated Intestine-407 cells and with undifferentiated or differentiated Caco-2 intestinal epithelial cells. Bacterial adhesion to and invasion of intestinal epithelial cells were assessed by counting CFU. The inhibitory effects of L. casei were determined after coincubation with adherent-invasive E. coli or after preincubation of intestinal cells with L. casei prior to infection with adherent-invasive E. coli. Inhibitory effects of L. casei on adherent-invasive E. coli adhesion to differentiated and undifferentiated intestinal epithelial cells reached 75% to 84% in coincubation and 43% to 62% in preincubation experiments, according to the cell lines used. Addition of L. casei culture supernatant to the incubation medium increased L. casei adhesion to intestinal epithelial cells and enhanced the inhibitory effects of L. casei. The inhibitory effects on E. coli invasion paralleled those on adhesion. This effect was not due to a bactericidal effect on adherent-invasive E. coli or to a cytotoxic effect on epithelial intestinal cells. As Lactobacillus casei DN-114 001 strongly inhibits interaction of adherent-invasive E. coli with intestinal epithelial cells, this finding suggests that the probiotic strain could be of therapeutic value in Crohn's disease.
Ingrassia
Isabelle
I
Pathogénie Bactérienne Intestinale, Laboratoire de Bactériologie, CBRV, 28 Place Henri Dunant, 63000 Clermont-Ferrand, France.
Leplingard
Antony
A
Darfeuille-Michaud
Arlette
A
D001422:Bacterial Adhesion / Q000502:physiology*; D018938:Caco-2 Cells; D002460:Cell Line; D003424:Crohn Disease / Q000382:microbiology* / Q000628:therapy; D004847:Epithelial Cells / Q000382:microbiology; D004926:Escherichia coli / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D007422:Intestines / Q000166:cytology / Q000382:microbiology*; D007780:Lacticaseibacillus casei / Q000254:growth & development / Q000502:physiology*; D019936:Probiotics / Q000627:therapeutic use*